PIPELINE OVERVIEW

There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases.

Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular therapies for the treatment of debilitating neurodegenerative diseases.

NurOwn® MSC-NTF Cells Platform

IndicationPreclinicalIND EnablingPhase 1Phase 2Phase 3
Amyotrophic Lateral Sclerosis
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Progressive Multiple Sclerosis

Rights: Phase 2 Ongoing

Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Alzheimer’s Disease
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Parkinson’s Disease
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Huntington’s Disease
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Autism Spectrum Disorder
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Peripheral Nerve Injury
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3

NurOwn® MSC-NTF Cells Exosomes off the shelf platform

IndicationPreclinicalIND EnablingPhase 1Phase 2Phase 3
ARDS
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Scroll to Top